Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes

• Main Authors: Dario Giugliano, Miriam Longo, Lorenzo Scappaticcio, Paola Caruso, Katherine Esposito
• Format: Article
• Language: English
• Published: BMC 2021-01-01
• Series: Cardiovascular Diabetology
• Subjects: SGLT-2 inhibitors; Type 2 diabetes; MACE; Heart failure; Diabetic kidney disease; Age
• Online Access: https://doi.org/10.1186/s12933-021-01213-w

Abstract Hospitalization for major diabetes complications, including myocardial infarction, stroke, lower-extremity amputation, and end-stage kidney disease, is on the rise and represents a great health burden for patients with type 2 diabetes (T2D), in particular for older people. Newer glucose-lowering medications have generated some optimism on the possibility to influence the natural history of cardiorenal complications of T2D. This review summarizes work in the area of sodium–glucose cotransporter 2 inhibitors (SGLT-2i) treatment and prevention of cardiorenal complications in patients with T2D (major adverse cardiovascular events, hospitalization for heart failure, kidney outcomes), with a particular emphasis on the effect of age, the role of primary versus secondary prevention and the possible extension of their cardiorenal benefits to the entire class of SGLT-2i.